Effect of naringenin on natural killer cell cytotoxicity against hepatocellular carcinoma cells in vitro and its mechanism

Lijie MA; Chang YU; Fang WANG; Yifei TANG; Hailong WU; Xuehua SUN; Yueqiu GAO

doi:10.3969/j.issn.1001-5256.2022.08.019

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1819-1824

PDF( 3514 KB)

Effect of naringenin on natural killer cell cytotoxicity against hepatocellular carcinoma cells in vitro and its mechanism

DOI: 10.3969/j.issn.1001-5256.2022.08.019

Lijie MA^{1, 2a, 2b},
Chang YU^2b,
Fang WANG^2b,
Yifei TANG^2a,
Hailong WU³,
Xuehua SUN^2a,
Yueqiu GAO^{2a
,
,
,}

1.
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2a.
Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2b.
Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3.
Shanghai University of Medicine & Health Sciences, Shanghai 201203, China

Research funding:

General Project of National Natural Science Foundation of China (81874436);

The State "AIDS and Viral Hepatitis and Other Major Infectious Diseases Prevention and treatment" Science and Technology Major Project (2018ZX10725504);

Youth Project of National Natural Science Foundation of China (81904117)

More Information

Corresponding author: GAO Yueqiu, gaoyueqiu@hotmail.com(ORCID: 0000-0001-7276-9810)
Received Date: 2021-11-09
Accepted Date: 2022-02-28
Published Date: 2022-08-20

Abstract

Abstract

Objective To investigate the effect of naringenin on the killing rate of natural killer (NK) cells and related mechanism by amplification of human peripheral blood mononuclear cells into NK cells in vitro and co-culture with hepatocellular carcinoma (HCC) CLC5 cells at a ratio of 1∶ 1. Methods A lymphocyte separation medium was used to isolate human peripheral blood mononuclear cells, which were induced with recombinant human interleukin-2 in vitro to culture NK cells. CCK-8 assay was used to measure the proliferation of HCC cells after human HCC cells were treated with naringenin (0, 3.125, 6.25, 12.5, 25, and 50 μmol/L) for 0, 24, and 48 hours, and after human NK cells were treated with different concentrations of naringenin for 24 hours, CCK-8 assay was used to measure the proliferation of NK cells. CellTiter-LumiTM was used to measure the killing rate of NK cells after the NK-HCC cell co-culture system at the ratio of 1∶ 1 was treated with naringenin for 24 hours. Quantitative real-time PCR was used to measure the gene expression of the activating receptor NKG2D in NK cells and NKG2D ligands in HCC cells. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results After being induced and cultured by recombinant human interleukin-2, NK cells were amplified to 82.33%±0.70% of human peripheral blood mononuclear cells. After naringenin treatment for 24 hours, there was no significant difference in the proliferation rate of HCC CLC5 cells between all mass concentration groups (all P > 0.05), and in the 25 and 50 μmol/L mass concentration groups, naringenin significantly promoted the proliferation of NK cells (both P < 0.000 1). After the NK-HCC cell co-culture system at the ratio of 1∶ 1 was treated with naringenin for 24 hours, there was a significant increase in the killing rate of NK cells in the 25 and 50 μmol/L mass concentration groups (both P < 0.000 1). After the co-culture system was treated with naringenin for 24 hours, naringenin had no effect on the expression of NKG2D in NK cells in the 25 and 50 μmol/L mass concentration groups, and it also had no effect on the expression of MICB and ULBP2 in HCC cells (all P > 0.05); it significantly upregulated the expression of the NKG2D ligands such as ULBP1 and ULBP3 in HCC cells (all P < 0.001). Conclusion Naringenin may increase the killing activity of NK cells by upregulating the expression of NKG2D ligands in HCC cells.
- Carcinoma, Hepatocellular,
- Naringin,
- Natural Killer T-Cells,
- Immunotherapy

FullText(HTML)

References(22)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer(2021 edition)[J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008. 中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
[2]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Professional Committee for Hepatology, Chinese Research Hospital Association; Chinese Society of Hepatology, Chinese Medical Association, et al. Guideline for stratified screening and surveillance of primary liver cancer(2020 edition)[J]. J Clin Hepatol, 2021, 37(2): 286-295. DOI: 10.3969/j.issn.1001-5256.2021.02.009. 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(2): 286-295. DOI: 10.3969/j.issn.1001-5256.2021.02.009.
[3]	National Health and Family Planning Commission of the P.R.C. Diagnosis, management, and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol, 2017, 33 (8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[4]	ZHONG XD, HE SQ, WEN B, et al. Mechanism of Biejiajian Wan against EMT of hepatocellular carcinoma cells through NF-κB signaling pathway[J]. Chin J Exp Med Formul, 2022, 28(1): 24-32. DOI: 10.13422/j.cnki.syfjx.20212421. 钟晓丹, 贺松其, 文彬, 等. 鳖甲煎丸通过NF-κB信号通路抑制肝癌细胞上皮间质转化的作用机制[J]. 中国实验方剂学杂志, 2022, 28(1): 24-32. DOI: 10.13422/j.cnki.syfjx.20212421.
[5]	XIE CY, XIE G, JI YZ. Naringenin inhibits NLRP3 inflammasome through miR-22 and reduces intestinal barrier damage in a rat model of ulcerative colitis[J]. Chin J Pathophysiol, 2021, 37(9): 1573-1581. DOI: 10.3969/j.issn.1000-4718.2021.09.005. 谢春燕, 谢刚, 季语竹. 柚皮素通过miR-22抑制NLRP3炎症小体并减轻溃疡性结肠炎大鼠模型肠屏障损伤[J]. 中国病理生理杂志, 2021, 37(9): 1573-1581. DOI: 10.3969/j.issn.1000-4718.2021.09.005.
[6]	JOSHI R, KULKARNI YA, WAIRKAR S. Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: An update[J]. Life Sci, 2018, 215: 43-56. DOI: 10.1016/j.lfs.2018.10.066.
[7]	ZENG WF, ZHANG FY, DU GJ, et al. Research updates on a novel immunomodulator, naringenin[J]. Prog Biochem Biophysics, 2018, 45(9): 915-925. DOI: 10.16476/j.pibb.2018.0189. 曾文峰, 张发云, 杜刚军, 等. 柚皮素: 新一代免疫调节剂[J]. 生物化学与生物物理进展, 2018, 45(9): 915-925. DOI: 10.16476/j.pibb.2018.0189.
[8]	BALD T, KRUMMEL MF, SMYTH MJ, et al. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies[J]. Nat Immunol, 2020, 21(8): 835-847. DOI: 10.1038/s41590-020-0728-z.
[9]	XU L, WANG Y, CHEN FX, et al. The effect of wogonin on NK cell cytotoxicity against gastric cancer MKN45 cells in vitro and the mechanism[J]. Immunol J, 2014, 30(9): 804-808. DOI: 10.13431/j.cnki.immunol.j.20140176. 许琳, 王营, 陈复兴, 等. 汉黄芩素对人NK细胞杀伤胃癌MKN45细胞的影响及其机制研究[J]. 免疫学杂志, 2014, 30(9): 804-808. DOI: 10.13431/j.cnki.immunol.j.20140176.
[10]	XU Z, ZHU X, SU L, et al. A high-throughput assay for screening natural products that boost NK cell-mediated killing of cancer cells[J]. Pharm Biol, 2020, 58(1): 357-366. DOI: 10.1080/13880209.2020.1748661.
[11]	MORVAN MG, LANIER LL. NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer, 2016, 16(1): 7-19. DOI: 10.1038/nrc.2015.5.
[12]	BALD T, KRUMMEL MF, SMYTH MJ, et al. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies[J]. Nat Immunol, 2020, 21(8): 835-847. DOI: 10.1038/s41590-020-0728-z.
[13]	WANG S, LONG S, WU W. Application of traditional Chinese medicines as personalized therapy in human cancers[J]. Am J Chin Med, 2018, 46(5): 953-970. DOI: 10.1142/S0192415X18500507.
[14]	HUANG Y, ZHU J, LIN X, et al. Potential of fatty oils from traditional chinese medicine in cancer therapy: a review for phytochemical, pharmacological and clinical studies[J]. Am J Chin Med, 2019, 47(4): 727-750. DOI: 10.1142/S0192415X19500381.
[15]	CUI GT, SHAO M, SHI HL. Shao Ming's experience in treating primary liver cancer[J]. J Changchun Univ Chin Med, 2020, 36(3): 439-441. DOI: 10.13463/j.cnki.cczyy.2020.03.010. 崔桂婷, 邵铭, 史会连. 邵铭论治原发性肝癌[J]. 长春中医药大学学报, 2020, 36(3): 439-441. DOI: 10.13463/j.cnki.cczyy.2020.03.010.
[16]	GHANBARI-MOVAHED M, JACKSON G, FARZAEI MH, et al. A systematic review of the preventive and therapeutic effects of naringin against human malignancies[J]. Front Pharmacol, 2021, 12: 639840. DOI: 10.3389/fphar.2021.639840.
[17]	ERDOGAN S, DOGANLAR O, DOGANLAR ZB, et al. Naringin sensitizes human prostate cancer cells to paclitaxel therapy[J]. Prostate Int, 2018, 6(4): 126-135. DOI: 10.1016/j.prnil.2017.11.001.
[18]	ALBAYRAK D, DOǦANLAR O, ERDOǦAN S, et al. Naringin combined with NF-κB inhibition and endoplasmic reticulum stress induces apoptotic cell death via oxidative stress and the PERK/eIF2α/ATF4/CHOP axis in ht29 colon cancer cells[J]. Biochem Genet, 2021, 59(1): 159-184. DOI: 10.1007/s10528-020-09996-5.
[19]	SHI GH, ZHOU SP, XU DS, et al. Killing effect of amplified NK cells on gastric cancer cells and its mechanism[J]. J Jilin Univ (Med Edit), 2020, 46(3): 530-535, insert 6. DOI: 10.13481/j.1671-587x.20200317. 石光环, 周世平, 徐东升, 等. 扩增的NK细胞对胃癌细胞的杀伤作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(3): 530-535, 后插6. DOI: 10.13481/j.1671-587x.20200317.
[20]	WU HF, ZHANG DY, ZHANG HY, et al. Effect and mechanism of IL-2 combined with IL-27 on natural killer cell against colorectal cancer cells[J]. Chin J Gerontol, 2021, 41(24): 5749-5752. DOI: 10.3969/j.issn.1005-9202.2021.24.069. 吴红芳, 张冬云, 张海燕, 等. IL-2联合IL-27对NK细胞杀伤结直肠癌细胞的作用及机制[J]. 中国老年学杂志, 2021, 41(24): 5749-5752. DOI: 10.3969/j.issn.1005-9202.2021.24.069.
[21]	DING H, YANG X, WEI Y. Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy[J]. Int J Mol Sci, 2018, 19(1): 177. DOI: 10.3390/ijms19010177.
[22]	LANIER LL. NKG2D receptor and its ligands in host defense[J]. Cancer Immunol Res, 2015, 3(6): 575-582. DOI: 10.1158/2326-6066.CIR-15-0098.

Relative Articles

[1]	Yuan ShengXian, Zhou WeiPing. Conversion therapy for hepatocellular carcinoma: Strategies and methods[J]. Journal of Clinical Hepatology, 2020, 36(2): 252-257. doi: 10.3969/j.issn.1001-5256.2020.02.002
[2]	Zhu ZeMin, Zhao ZhiJian, Tang CaiXi. Research advances in apatinib combined with transcatheter arterial embolization in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2325-2328. doi: 10.3969/j.issn.1001-5256.2020.10.036
[3]	Yang Jun, Yin Yu, Ni CaiFang, Zhu XiaoLi, Li Zhi, Zhang Shen, Huang Peng, Wang WanSheng. Value of ABCR scoring system in assessing the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2020.09.014
[4]	Wang ZheXuan, Wang EnXin, Xia DongDong, Bai Wei, Wang QiuHe, Yuan Jie, Li XiaoMei, Niu Jing, Guo WenGang, Li Kai, Yin ZhanXin, Han GuoHong. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(1): 113-117. doi: 10.3969/j.issn.1001-5256.2020.01.025
[5]	Tang HaoHuan, Zhu XiaoLi, Wang WanSheng, Li WanCi, Zhou LinFeng, Du Hang. Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1509-1513. doi: 10.3969/j.issn.1001-5256.2019.07.018
[6]	Wang YuZhe, Yin HuaBin. Feasibility of i Flow color-coding technique in quantitative real-time measurement of hemodynamic changes after transarterial chemoembolization for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 133-136. doi: 10.3969/j.issn.1001-5256.2018.01.027
[7]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[8]	Liu BoZhi, Yuan ZhuHui, Li Wei. A case of large hepatocellular carcinoma treated by transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. Journal of Clinical Hepatology, 2018, 34(7): 1520-1522. doi: 10.3969/j.issn.1001-5256.2018.07.031
[9]	Wu Lei, Wang Su. Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(4): 867-871. doi: 10.3969/j.issn.1001-5256.2018.04.037
[10]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[11]	Li Xin. Short-and long-term efficacy of transarterial chemoembolization versus liver resection in treatment of patients with Barcelona stage B multiple hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1296-1300. doi: 10.3969/j.issn.1001-5256.2017.07.018
[12]	Dong DeShuo, Liu ZhaoYu. Research advances in Huai'er granules combined with transarterial chemoembolization in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(10): 2021-2024. doi: 10.3969/j.issn.1001-5256.2017.09.10.037
[13]	Zhou YiLong, Chen Yuan, Zhang YiXin, Shao BingFeng, Zhang SuQing, Xu AiBing, He Song, Li YongJun, Tian SiYuan. Influence of Forkhead box Q1 expression on therapeutic effect of transarterial chemoembolization after hepatocellular carcinoma surgery[J]. Journal of Clinical Hepatology, 2016, 32(11): 2126-2129. doi: 10.3969/j.issn.1001-5256.2016.11.024
[14]	Wang WenJun, Zhao Yan, Xia DongDong, Wang EnXin, Liu Lei, Han GuoHong. Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2016, 32(6): 1139-1144. doi: 10.3969/j.issn.1001-5256.2016.06.024
[15]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[16]	Ma JingFan, Chen Gang, Liu Hong. TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response[J]. Journal of Clinical Hepatology, 2016, 32(1): 152-154. doi: 10.3969/j.issn.1001-5256.2016.01.030
[17]	Luo YongHeng, Xiao EnHua. Role of functional magnetic resonance imaging in evaluating the therapeutic effect of transcatheter arterial chemoembolization in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(12): 2277-2281. doi: 10.3969/j.issn.1001-5256.2016.12.010
[18]	Gao Sheng, Liu JianYong, Zhang ZhiMing, Zhao YinNong, Yuan WeiPing, Wu FeiXiang, Xiang BangDe. Efficacy of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma before hepatectomy:a meta-analysis[J]. Journal of Clinical Hepatology, 2014, 30(9): 917-920. doi: 10.3969/j.issn.1001-5256.2014.09.020
[19]	Zhang Cheng, Chen ChangNan, Lin YunXiao, Su MingJun, Pan QiZuo, Chen ChanJuan, Rong TingJie, Xie Feng. Clinical effect of transcatheter arterial chemoembolization combined with tegafur, gimeracil, and oteracil potassium in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(1): 55-57. doi: 10.3969/j.issn.1001-5256.2014.01.012
[20]	Xin GuiJie, Zhuang ShuWu, Cai YanJun, Zhang DaWei, Chi XiuMei, Niu JunQi. Clinical study of antiviral treatment combined with transcatheter arterial chemoemholization (TACE) in patients with hepatitis B cirrhosis complicated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(4): 267-269.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	李炎，孙永岑. 专科护士主导的O2O多学科管理在肝硬化代偿期患者中的应用. 临床护理杂志. 2024(05): 39-43 .
2.	郝志明，窦琴，包晓云. 基于PI3K/Akt信号通路探讨肝康片对四氯化碳致肝纤维化大鼠肝功能的保护机制. 现代消化及介入诊疗. 2020(02): 188-192 .
3.	朱豫萌，朱丹燕，张国强. 中西药合用治疗慢性乙型病毒性肝炎疗效观察. 实用中医药杂志. 2019(09): 1101-1103 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (618) PDF downloads(63)

Effect of naringenin on natural killer cell cytotoxicity against hepatocellular carcinoma cells in vitro and its mechanism

DOI: 10.3969/j.issn.1001-5256.2022.08.019